Dr Priya Sumithran is a clinician researcher. She completed a PhD at the University of Melbourne and currently leads the Clinical and Translational Obesity Research Group in the Dept of Medicine (Austin), which focuses on understanding the regulation of body weight, appetite and eating behaviours, with a view to improving the treatment of obesity.
She is also an endocrinologist at Austin Health, where she is co-leader of the medical obesity treatment service. Her other current roles include council member of Australian and New Zealand Obesity Society (ANZOS) and associate editor of Clinical Obesity.
Find out more about Priya Sumithran's experience
Priya Sumithran's highlights
Priya Sumithran's selected work
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, rando..
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND r..
Displaying the 4 most recent projects by Priya Sumithran.
Displaying the 37 most recent scholarly works by Priya Sumithran.
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, Rafael Diaz, Mark Lakshmanan, Prem Pais, Jeffrey Probstfield, Jeffrey S Riesmeyer, Matthew C Riddle, Lars Rydén, Denis Xavier, Charles Messan Atisso, Leanne Dyal, Stephanie Hall, Purnima Rao-Melacini, Gloria Wong, Alvaro Avezum, Jan Basile, Namsik Chung, Ignacio Conget, et al.
Journal article | 2019 | The Lancet
BACKGROUND: Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascular outcomes in people with type 2..
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, Rafael Diaz, Mark Lakshmanan, Prem Pais, Jeffrey Probstfield, Fady T Botros, Matthew C Riddle, Lars Rydén, Denis Xavier, Charles Messan Atisso, Leanne Dyal, Stephanie Hall, Purnima Rao-Melacini, Gloria Wong, Alvaro Avezum, Jan Basile, Namsik Chung, Ignacio Conget, et al.
Journal article | 2019 | The Lancet
BACKGROUND: Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal outcomes in people with type 2 diabetes at risk fo..
Routine use of HbA1c amongst inpatients hospitalised with decompensated heart failure and the association of dysglycaemia with outcomes
K Khoo, J Lew, P Neef, L Kearney, L Churilov, R Robbins, A Tan, M Hachem, L Owen-Jones, Q Lam, GK Hart, A Wilson, P Sumithran, D Johnson, PM Srivastava, O Farouque, LM Burrell, JD Zajac, EI Ekinci
Journal article | 2018 | Scientific Reports
Clinical Obesity Services in Public Hospitals in Australia: a position statement based on expert consensus
E Atlantis, N Kormas, K Samaras, P Fahey, P Sumithran, S Glastras, G Wittert, K Fusco, R Bishay, T Markovic, L Ding, K Williams, I Caterson, V Chikani, P Dugdale, J Dixon
Journal article | 2018 | Clinical Obesity
Using Automated HbA1c Testing to Detect Diabetes Mellitus in Orthopedic Inpatients and Its Effect on Outcomes
Elif I Ekinci, Alvin Kong, Leonid Churilov, Natalie Nanayakkara, Wei Ling Chiu, Priya Sumithran, Frida Djukiadmodjo, Erosha Premaratne, Elizabeth Owen-Jones, Graeme Kevin Hart, Raymond Robbins, Andrew Hardidge, Douglas Johnson, Scott T Baker, Jeffrey D Zajac
Journal article | 2017 | PLoS One
Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.
undefined DREAM Trial Investigators, GR Dagenais, HC Gerstein, R Holman, A Budaj, A Escalante, T Hedner, M Keltai, E Lonn, S McFarlane, M McQueen, K Teo, P Sheridan, J Bosch, J Pogue, S Yusuf
Journal article | 2008 | Diabetes Care
OBJECTIVE: Impaired glucose tolerance (IGT) and/or impaired fasting glucose (IFG) are risk factors for diabetes, cardiovascular di..
Ketogenic diets for weight loss: A review of their principles, safety and efficacy.
Priya Sumithran, Joseph Proietto
Journal article | 2008 | Obesity Research & Clinical Practice
SUMMARY: Low-carbohydrate "ketogenic" diets have increased in popularity over recent years as a means of weight loss. Published st..
Prospective evaluation of a protocol for reduced glucocorticoid replacement in transsphenoidal pituitary adenomectomy: prophylactic glucocorticoid replacement is seldom necessary
John M Wentworth, Nicole Gao, Kalpana P Sumithran, Niki F Maartens, Andrew H Kaye, Peter G Colman, Peter R Ebeling
Journal article | 2008 | Clinical Endocrinology
Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention).
undefined Origin Trial Investigators, Hertzel Gerstein, Salim Yusuf, Matthew C Riddle, Lars Ryden, Jackie Bosch
Journal article | 2008 | American Heart Journal
AIMS: Impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and diabetes arise due to insufficient insulin secretion a..
Effect of ramipril on the incidence of diabetes.
undefined DREAM Trial Investigators, Jackie Bosch, Salim Yusuf, Hertzel C Gerstein, Janice Pogue, Patrick Sheridan, Gilles Dagenais, Rafael Diaz, Alvaro Avezum, Fernando Lanas, Jeffrey Probstfield, George Fodor, Rury R Holman
Journal article | 2006 | New England Journal of Medicine
BACKGROUND: Previous studies have suggested that blockade of the renin-angiotensin system may prevent diabetes in people with card..
Honours, Awards and Fellowships
Emerging Health Researcher of the Year
Best Clinical Paper
Shields Research Entry Scholarship
FRACP - Fellow of the Royal Australasian College of Physicians
David Bickart Clinical Research Fellow
Medicine - Austin Health
Australian and New Zealand Obesity Society
The Obesity Society
Endocrine Society of Australia
Australian Diabetes Society
Doctor of Philosophy
University of Melbourne
Bachelor of Medicine Bachelor of Surgery (Honours)
University of Melbourne